Consultation wasrequest from the opthalmology department and the diagnosis was reported as Panuveitis. Steroid eye drops were started and she was referred to the rheumatology department for systemic treatment .We started the patient on Secukinumab 150 mg /week ,Meloxicam 15 mg /day ,Vit D 50000 IU/week ,Calcium ,PPI 40 mg during 2 month ago. The Endocrine department diagnosed Hashimato , Eutirox 150 mkg /day as treatment.

Conclusion

I am sharing with you the the control results after 2 months. During eye control ,his vision was 70 % better .There was no complains of pain or redness. ESR-15 mm /30 min ,Crp-4,8 mg /l ,Rf-8.5 IU /ml ,ALT- 17.7 U /L ,AST-15.7 ,TSH-5.2.Patient felt better.There was no knee pain and swelling , back pain or stiffness in the mornings.The patient was advised to continue her rheumatological treatment and swim 3 days a week .AxSpA, comprising r-axSpA and nr-axSpA, covers a whole spectrum of disease with different courses. Therapy with bDMARDs should be considered for patients who are refractory to first-line NSAIDs. TNF and IL- 17A inhibition were shown to be efficacious in patients whose disease is not adequately controlled by NSAIDs.This clinical results showed us that Secukinumab also helps improve eye symptoms